David M. Knott Jr’s Protagonist Therapeutics PTGX Stock Holding History

David M. Knott Jr’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.72M	Hold	63,000	–	–	4.08%	6
2026 Q1	$6.64M	Sell	63,000 -10,000	-14%	-$885K	3.95%	5
2025 Q4	$6.38M	Sell	73,000 -10,000	-12%	-$818K	2.95%	8
2025 Q3	$5.51M	Buy	83,000 +3,000	+4%	+$171K	2.22%	11
2025 Q2	$4.42M	Buy	80,000 +4,000	+5%	+$192K	2%	9
2025 Q1	$3.68M	Buy	76,000 +23,632	+45%	+$990K	1.73%	12
2024 Q4	$2.02M	Hold	52,368	–	–	0.73%	21
2024 Q3	$2.36M	Hold	52,368	–	–	0.83%	29
2024 Q2	$1.81M	Hold	52,368	–	–	0.72%	30
2024 Q1	$1.51M	Hold	52,368	–	–	0.54%	35
2023 Q4	$1.2M	Hold	52,368	–	–	0.46%	30
2023 Q3	$873K	Buy	+52,368	New	+$1.02M	0.33%	41

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

David M. Knott Jr's PTGX Position: Q2 2026 in Review

David M. Knott Jr held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 63,000 shares worth $7.72M. The position accounts for 4.08% of the portfolio, ranked #6.

David M. Knott Jr first reported a position in PTGX in Q3 2023 and has held it in 12 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

David M. Knott Jr held 63,000 shares of Protagonist Therapeutics worth $7.72M as of Q2 2026.
David M. Knott Jr left its Protagonist Therapeutics share count unchanged in Q2 2026.
Protagonist Therapeutics made up 4.08% of David M. Knott Jr's portfolio in Q2 2026, its #6 holding.
David M. Knott Jr first reported a position in Protagonist Therapeutics in Q3 2023 and has held it in 12 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.